Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dorgenmeltucel-L
- Development stage
- Phase 2
- Lead developer
- Lumos Pharma
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intradermal, Subcutaneous
01
Overview
Dorgenmeltucel-L is an investigational allogeneic whole-cell cancer vaccine comprised of genetically engineered melanoma cell lines that express alpha-1,3-galactosyltransferase to display alpha-Gal epitopes, designed to provoke a strong innate and adaptive immune response against melanoma antigens when the non-self alpha-Gal is recognized and targeted by pre-existing natural antibodies, thereby promoting tumor cell killing and antigen spreading. It was originated by NewLink Genetics and further developed by Lumos Pharma, primarily for malignant melanoma; clinical studies also explored combination immunotherapy settings. Phase I/II studies reported immune activation (universal seroconversion) and signals of clinical activity in advanced melanoma, and the program remained in Phase II for melanoma per public pipeline summaries. The approach belongs to NewLink’s HyperAcute platform of allogeneic, alpha-Gal–expressing tumor cell vaccines.
- Brand names
- HyperAcute-Melanoma
- Other names
- HyperAcute Melanoma
Beyond the preview
Go deeper on dorgenmeltucel-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dorgenmeltucel-L.